In a major win for the cigar industry, the U.S. Court of Appeals for the District of Columbia ruled that the FDA’s regulation of premium cigars was “arbitrary and capricious,” overturning its application under the Deeming Rule.
The Court upheld a lower court’s decision, stating that the FDA ignored key evidence on premium cigars’ risk profile. As a result, the rule has been vacated, though the case will return to the district court for further clarification on defining a “premium cigar.”
“This is a great victory for the cigar industry,” said Cigar Association of America (CAA) Chairman Javier Estades. CAA President Scott Pearce echoed the sentiment, emphasizing the importance of a fair regulatory framework for manufacturers, retailers, and consumers.
The case will proceed in March when the mandate is issued.
Short Link: